Saturday 17 October 2026
Export COGT’s income statement to Excel — free account
Cogent Biosciences, Inc.
COGT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 1.89% and free cash flow fell 42.0%, each against the same quarter a year earlier.
29.52
0.01
+0.03%
Follow COGT
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 3 | 2 | 3 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z-Score |
— | — | 0.57 | (3.79) | 3.55 | — | — | — | — | — |
P/S ratio |
13.52 | 13.52 | 11.25 | 0.98 | 5.37 | — | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
2.23 | (3.34) | 0.43 | (7.03) | 16.44 | — | — | — | — | — |
P/Operating CF |
(17.39) | (17.39) | (12.14) | (2.60) | (13.29) | — | — | — | — | — |
Beneish M-Score |
— | (1.92) | (2.20) | 1.63 | — | — | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 1.82 | 0.69 | 1.01 | — | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 1.82 | 0.69 | 1.01 | — | — | — | — | — |
EV/Sales |
8.62 | 8.62 | 3.18 | (0.49) | (4.95) | — | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.36 | 1.41 | — | — | — | — | — |
EV/Operating CF |
(2.80) | (2.80) | (0.95) | 0.27 | 3.20 | — | — | — | — | — |
EV/FCF |
(2.70) | (2.70) | (0.94) | 0.27 | 4.21 | — | — | — | — | — |
Quick Ratio |
7.95 | 3.74 | 3.22 | 2.98 | 18.50 | 12.86 | 9.70 | 6.96 | 5.15 | 14.08 |
Current Ratio |
7.98 | 3.79 | 3.25 | 3.06 | 18.70 | 13.04 | 9.87 | 7.09 | 5.32 | 14.23 |
Net Debt/EBITDA |
3.76 | 1.64 | 2.25 | 1.07 | 2.93 | 2.90 | 1.63 | 1.26 | 1.02 | 2.04 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 8.93% | 1.26% | 0.36% | 6.06% | 0.00% | 0.00% | 23.77% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.14 | 0.01 | 0.00 | 0.07 | 0.00 | 0.00 | 0.35 |
Asset Turnover |
0.17 | 0.13 | 0.14 | 0.33 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.02 | 1.01 | 0.94 | 1.30 | 0.20 | 0.81 | 0.85 | 0.80 | 0.81 | 0.80 |
Capex/Depreciation |
(3.90) | (0.77) | (0.51) | 0.14 | 11.69 | (11.69) | 8.62 | 0.96 | 0.11 | (1.29) |
Interest Coverage |
(71.96) | (67.75) | (31.23) | (120.52) | (570.83) | (161.78) | (37.06) | — | — | (108.87) |
| 49.46% | 69.50% | (606.74%) | (69.21%) | (230.42%) | (57.23%) | (88.01%) | (99.26%) | (148.99%) | (94.98%) | |
| (48.15%) | (41.00%) | (51.17%) | (47.04%) | (119.34%) | (29.93%) | (52.63%) | (62.65%) | (79.79%) | (51.99%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (688.01%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(27.74%) | (72.41%) | (58.25%) | (108.99%) | (77.26%) | (34.87%) | (57.03%) | (79.86%) | (103.49%) | (38.61%) |
Average Days of Receivables |
53.30 | 36.24 | 62.55 | 32.45 | 0.00 | — | — | — | — | — |
Research and Development Expense of Revenue |
346.06% | 356.84% | 393.31% | 194.27% | 922.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
54.02% | 55.98% | 76.58% | 48.75% | 221.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
15.99% | 16.04% | 31.72% | 14.41% | 76.45% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.49) | (0.49) | 0.50 | 1.04 | 1.84 | — | — | — | — | — |
Graham Number |
0.00 | 65.69 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
Earnings Yield |
(22.51%) | (22.51%) | (36.36%) | (307.71%) | (114.78%) | — | — | — | — | — |
Free Cash Flow Yield |
(23.61%) | (23.61%) | (30.16%) | (188.39%) | (21.87%) | — | — | — | — | — |
Revenue per Share |
2.49 | 3.28 | 1.56 | 2.95 | 0.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(7.32) | (10.14) | (5.22) | (5.45) | (3.24) | (1.52) | (2.02) | (1.93) | (2.00) | (2.05) |
Capex per Share |
(1.30) | (0.36) | (0.09) | 0.02 | 0.76 | (0.04) | (0.12) | (0.04) | (0.01) | (0.01) |
Free Cash Flow per Share |
(8.62) | (10.50) | (5.31) | (5.43) | (2.48) | (1.56) | (2.14) | (1.96) | (2.01) | (2.06) |
Cash per Share |
26.89 | 16.11 | 12.63 | 4.91 | 21.86 | 5.67 | 4.44 | 3.34 | 2.76 | 6.99 |
Shareholders Equity per Share |
(9.69) | (19.17) | 9.68 | 4.17 | 21.18 | 5.53 | 4.35 | 3.24 | 2.47 | 4.94 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(9.69) | (19.17) | 9.68 | 4.17 | 21.18 | 5.53 | 4.35 | 3.24 | 2.47 | 4.94 |
Free Cash Flow |
(21.95) | (26.75) | (33.04) | (41.34) | (27.43) | (60.48) | (125.50) | (156.42) | (208.36) | (266.00) |
Working Capital |
61.00 | 31.19 | 56.06 | 27.34 | 231.82 | 205.56 | 238.12 | 232.60 | 240.76 | 846.40 |
Capital Expenditures |
(3.31) | (0.91) | (0.55) | 0.17 | 8.42 | (1.72) | (6.86) | (2.80) | (0.57) | (1.55) |
Net Current Asset Value |
(30.52) | (55.58) | 55.31 | 22.93 | 228.66 | 204.73 | 219.89 | 215.14 | 224.86 | 609.12 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.34 | 1.39 | — | — | — | — | — |
Capex to Sales |
0.52 | 0.11 | 0.06 | (0.01) | (1.07) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.19 | 0.29 | 0.33 | 0.66 | 5.37 | 0.09 | (0.10) | (0.35) | (0.80) | 0.22 |
Cash ROIC |
(50.10%) | 342.47% | (23.80%) | (56.17%) | (5.71%) | (13.91%) | (23.48%) | (29.88%) | (38.35%) | (15.11%) |
Accounts Receivable Turnover |
7.23 | 9.51 | 7.79 | 12.27 | 0.00 | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
0.88 | 0.88 | 1.25 | 1.83 | — | — | — | — | — | — |
Average Payables |
1.40 | 1.40 | 1.43 | 2.35 | 1.96 | 2.11 | 4.66 | 8.25 | 11.33 | 10.76 |
Average Assets |
37.78 | 62.33 | 67.52 | 67.68 | 150.17 | 241.50 | 266.45 | 307.12 | 320.67 | 632.75 |
Average Common Equity |
(36.77) | (36.77) | 5.69 | 46.00 | 77.77 | 126.29 | 159.34 | 193.84 | 171.73 | 346.33 |
Columns are period end dates